News und Analysen
EQS-Adhoc: Bio-Gate AG schließt Barkapitalerhöhung ab
EQS-Adhoc: elexxion AG informiert über Beschluss einer Kapitalerhöhung
DGAP-News: Maternus-Kliniken AG: Corona-Pandemie und Inflation beeinträchtigen Umsatz- und Ergebnisentwicklung
DGAP-News: Bio-Gate AG: Bio-Gate bestätigt vorläufige Halbjahreszahlen und angepassten Ausblick für 2022
DGAP-News: Bio-Gate erwartet trotz geopolitischer Unsicherheiten starke zweite Jahreshälfte 2022
DGAP-Adhoc: Bio-Gate AG passt Umsatz- und Ergebnisprognose für 2022 an
DGAP-Adhoc: Maternus-Kliniken AG: Anpassung der Prognose für das Geschäftsjahr 2022
DGAP-News: Bio-Gate AG: Bio-Gate schließt einen weiteren Kooperationsvertrag mit weltweit tätigem Implantat-Hersteller
DGAP-HV: Eifelhöhen-Klinik Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 12.07.2022 in Frankfurt mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-News: Maternus-Kliniken AG erzielt in 2021 bei Konzernumsatzerlösen von 111,4 Mio. € eine deutliche Ergebnisverbesserung. Für 2022 Konzernumsatz von bis zu 114,5 Mio. € erwartet.
Pulse Biosciences to Participate in the Stephens Annual Investment Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to
Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
Pulse Biosciences Reports Third Quarter 2021 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial
Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third
Veris Health Showcased in PAVmed Digital Health Virtual Investor Event
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, hosted a virtual investor event with several
Lucid Diagnostics Announces Pricing of Initial Public Offering
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)
PAVmed to Host Digital Health Virtual Investor Event
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that on October 26, 2021, from 1
BIOCORP und NOVO NORDISK schließen weltweite Partnerschaft im Bereich Diabetes und digitale Gesundheit
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen
BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, and its majority-owned subsidiary, Lucid Diagnostics Inc
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that its major subsidiary Veris
BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH)
Aufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen